Highlights Newsletter 1

This newsletter presents you the following key sessions:

1. Breast Cancer Index (BCI) risk scores prognostic in premenopausal patients with HR+ early stage breast
    cancer

2. First-line ribociclib plus endocrine therapy potentially more effective than combination chemotherapy in
    premenopausal patients with HR+/HER2- aggressive breast cancer

3. T-DXd yields superior outcomes over chemotherapy-based regimens in HER2-positive metastatic patients
    previously treated with T-DM1

4. Longer duration of prior CDK4/6 inhibitor results in a greater PFS benefit of elacestrant in patients with
    ER+/HER2- metastatic breast cancer

SMPC